{"name":"The United Bio-Technology (Hengqin) Co., Ltd.","slug":"the-united-bio-technology-hengqin-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"UBT251","genericName":"UBT251","slug":"ubt251","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"UBT251","genericName":"UBT251","slug":"ubt251","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxNM2NPbENwMzNpTUFEVm5KbDdlTmVpZnFTWmR1X20wYUdkSkhEdUk3RFd6QUxfTEhQcTd3bHRiOUpsVDBVa3pKQ0ZvNXpxMzBRVEVWRGJBdnVCQnlSaGMyT0lzY3EtbE9ac25uRmQ1WGszOVI3c1gyZkszak5FVmhPUElJU3Z0SmZnQVhTN0loVFFPMDUtYTIzVWlSa0NtVDg4cTR1OE9MaEVVM2dkM0cydmVFQkd4RUNQNmZrbUJMOC1GYkR2VV9Uci1LVDI0ck5kb0txZjN4V3NRTTZTWGw0QkN4eUpUbkdXRWpSV25mQlM3ZVM2LUlGM1ZxQWU1T3FhNUI1OU4tbWZLVG1FRThGbGhmd1p2d1hCWHdCNXpEdlpRejRZb1R5dWpFSQ?oc=5","date":"2026-03-26","type":"trial","source":"Media OutReach Newswire","summary":"Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes - Media OutReach Newswire","headline":"Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients w","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOVzlhbVhBWllZUzNjUlB1WmxaYUNpSWRHQ21HZk9XR3lOTktkcHJNM3BpcU1Ic3J0b2M2MXM0aG53SW05NkNibTFFV2xqOE1YNlFfUFMxTGxJaWplMmtRRTRsay1zYWh4MEFtWWVUaWdnSHcwQmdiQkZkeUMzem9ibXBYaHZUaUp4TG9HdDRseEhWMnZpLWRhTmR2eUl2MTJjT3VPbzA1aU9uT3kzNlpqR3hOS3JyWkpqZS1DYlZSLWNFWjA?oc=5","date":"2026-03-25","type":"trial","source":"TradingView","summary":"NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data - TradingView","headline":"NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE1hYkdPRDl2b29aZGcwVkFjY3lLNUZ2bVpvMnhUc1lXV0YtZWtGT2U5MVlIT3BVaGlnaGd3eE51eHhXak9OZmJ2SEJpLUZqMVR0YzBQajEtNVJuYjV2ekHSAWNBVV95cUxOcTdESUY4c002bmtoZ21LS0FqY1J6bmUyQk9NRkxSUi1kTnkzYWpLMnAyei1lV2VWVXpQMENPa2pwVUNZUThULUFHMk00UzlPeE82UkdTNkZ4cU9vX1hIVkV4eGc?oc=5","date":"2026-03-25","type":"trial","source":"Bitget","summary":"NVO Considers Worldwide Launch of Diabetes Medication Following Positive Phase II Results - Bitget","headline":"NVO Considers Worldwide Launch of Diabetes Medication Following Positive Phase II Results","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQbXVDa0dxREx2Y2NDMkJVR25IaTVMQi03TzhwdDlER1d3VDhUeUxEMmx2b3NtME9NNG1rWmMzUWhyN0Vyd3lyaHd0VzZqaTMxQ3hWQXZqOTM3Tm5UaGFCdmFDb1NrTkk5bHgzOFlvNlNTdXhhRW5wdldFUHhOVjVVWUJENnpLNk5aMlU2bDF4QkZ5T1lnaEY5ZEI5MkVJTEUwTVdXUEI1VTlpdEtwbmFoV2l4a3E3dlE0TExwRG5nSFAza2FIeDBsa01sdFpPdkY3b1FrQ1dsQWcyOWRjX29VSGJpdEd0VmgwYU9YcldyM1E1UQ?oc=5","date":"2026-02-24","type":"trial","source":"Media OutReach Newswire","summary":"Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China - Media OutReach Newswire","headline":"Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxPWjU0eDlCY0Y5OUpJUWRXc2hUdHRaV194bmJNdjJNWEdxNkVLVGVuQy1HSEQtM0tFX3NJNDNDQng0QmY5bjY1TklsczBKMnJhZU81dmZKSzI2WFptaHhjWDMycndHZk9yS2pmendlSEtncXJGdUJqQTA1U0k2WWdSYUdocEk0VzAwQ0xRakptLW1xaUEyOVFIeEtOeEJscHFVcU5UZlFnc0tneWl3NHBtVi1YVDhyX1ROTWRzQ2dSQlZua2RNX0xtYUxuNTdmazZrS1lhYUJtMkRETDFBTThQZlZTT1pyVTNTemo2V3VQVm8wc1VMYVdnOVZmdGIwNF9kWEpBWFhudDJoWDE2RFBicnN1ZzNjN0hkbnNBcUNxcHI1NzBrWVB6WU5vZ081Zw?oc=5","date":"2025-03-24","type":"pipeline","source":"GlobeNewswire","summary":"The United Laboratories and Novo Nordisk announce exclusive - GlobeNewswire","headline":"The United Laboratories and Novo Nordisk announce exclusive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQMXo2MkFXUjEzUnhPMkZSaU9zdl9haDFHVXQ3TXdObm94TnF4V0Y4UkVGU1Qxa1FRSDBnRHNuam1hcmNUOEJCWHZ1UElfcmFybUxTZE5ORk9FVjR0LVRBQkNXRkF6b1JkaFlDZk1PdGZyckdWX0l1WGhsSnJkaHRBd1pqY3RDZjJubElDOHBobm81eXBFdWRxX1d3cU0ydnJh?oc=5","date":"2025-03-24","type":"deal","source":"Contract Pharma","summary":"Novo Nordisk Secures Triple Agonist UBT251 in $2B Deal - Contract Pharma","headline":"Novo Nordisk Secures Triple Agonist UBT251 in $2B Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOajhYSVktVnhaWG9XZTEyZXFvc3lEd21zM1A2RDNEX0VsLWhEazFXS0JtejhhSy1nbFZMRmYxNW9fSHJCaG80SWxUUEZBUWhWUEhaOVRCeFczVEtUYWItWWIzd1diX2tuNnIwSXVnaC1iYUVISExfUFhmY2RFdkMzak96X041WE1lLTRyVDBEYUE4OExjS2ZkcWo2dTJzYzQtdVVsS0RRdzR0QW5YYnZiMUkyT1g4Y0h5SXhJakhKZElIYWtSV0c5VDUycw?oc=5","date":"2025-03-24","type":"deal","source":"wsj.com","summary":"Novo Nordisk Signs $2 Billion Deal for Experimental Obesity Drug - wsj.com","headline":"Novo Nordisk Signs $2 Billion Deal for Experimental Obesity Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxPSU04OVE2ZGFuYjRGTFF4Y2laNWJRRFZ1dDdCdnhiY05SUHpLaTZNeXBuamc2WlkyaktMd3FlU19FbDZZZnVMRlNKalVjRVphYmk4Y0dvVE5Kbl9GUTlLVGp0ZmNCVlFNOFNLUk1YaUpYaExsdXdkNDA3UlVpNDNIZDdRNzlZNmJDTm11VlF5ZVI3NGJIejhJNnZ3WUtFRUpnekZSRTBZdFRtZXpPX3NHRFh0TEtEZUxuS2duSE5PVEt4MUpjQ01Mal92MEhDYnZObTBEOFFDTnBTN0dVZkVHcWZ4OFdjWUpnQXlIOEFnZ0tKdV9TUlhwdmt2M19iZWcxVGNyalh0NkJjb0VDUzcwdUFPMVBDREM5YXJEeFRHWWphTDZWck85SUtR?oc=5","date":"2023-06-20","type":"trial","source":"Media OutReach Newswire","summary":"The United Laboratories International Holdings Limited Applies for the Clinical Trial of its Class 1 Innovative New Drug UBT251 Injection #TUL - Media OutReach Newswire","headline":"The United Laboratories International Holdings Limited Applies for the Clinical Trial of its Class 1 Innovative New Drug","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}